SAN DIEGO--(BUSINESS WIRE)--
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of John Peck Jr., to its Board of Directors. John Peck has been involved with the Company as an early-stage seed round investor and has taken an active role in overseeing the development of the ValloVax drug program.
“John brings a wealth of valuable experience to Batu and we look forward to his continued enthusiastic involvement as ValloVax progresses into US clinical trials,” stated Alan Lewis, Chairman of Batu’s Board of Directors.
John Peck Jr. graduated from Northern Illinois University in 1966 with a BS in Business. He spent the next three years in the US Army as an ordinance officer stationed in Southeast Asia. Upon returning to the States in 1969, he worked for RCA and Intel while pursuing an MBA at Depaul University. In 1976, John joined Meridian Leasing as employee number 5. In 1994, John (now CEO) and a Partner purchased Meridian Leasing and grew the company to 150 employees. John’s share was bought out in 1997 and he started investing in commercial real estate with an emphasis on large multifamily properties. Currently, John is doing less land development work and he believes that the “New Wave of the Future” lies within the biotechnology community. At present, he has invested in 7 Biotech firms.
“The rapid advances in the field of immuno-oncology and biotechnology have the potential to reshape our understanding of human health as we know it today,” stated John Peck Jr. “Batu’s technology seeks to revolutionize the anti-angiogenesis space for the treatment of cancer, and I am pleased to be involved with such an outstanding Team and technology.”
About Batu Biologics
Batu Biologics is an immuno-oncology company developing novel gene and cellular based therapies for the treatment of cancer. The Company has filed an IND application for its lead therapeutic, ValloVax™, a multivalent therapeutic vaccine for Non Small Cell Lung Cancer targeting several tumor-angiogenesis associated antigens. ValloVax™ has demonstrated strong inhibition of tumor growth in several histologically distinct tumor models, and the company is currently raising funds that will enable the completion of a Phase I clinical study.